Literature DB >> 7917775

Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin.

E Chan1, A J McLachlan, M Pegg, A D MacKay, R B Cole, M Rowland.   

Abstract

1. The disposition of warfarin enantiomers and metabolites has been studied in 36 patients receiving chronic rac-warfarin therapy, titrated to approximately the same anticoagulant response. 2. A stereoselective h.p.l.c. assay was employed to determine the concentrations of (R)- and (S)-warfarin, (R,S)-warfarin alcohol and (S)-7-hydroxywarfarin in plasma and 24 h urine samples. The concentrations of (R)-7-hydroxywarfarin, (S,S)-warfarin alcohol and (R)-6- and (S)-6-hydroxywarfarin were also determined in urine samples. The fractions unbound of warfarin enantiomers were determined using equilibrium dialysis. 3. Wide variability was observed in daily dose requirements (mean 6.1 mg; range: 2.5-12 mg), in plasma concentrations of (S)-warfarin (0.48 mg l(-1); 0.11-1.02 mg l(-1)), (R)-warfarin (0.87 mg l(-1); 0.29-1.82 mg l(-1)), (R,S)-warfarin alcohol (0.31 mg l(-1); 0.02-0.72 mg l(-1)) and (S)-7-hydroxywarfarin (0.25 mg l(-1); 0.07-0.37 mg l(-1)) and the percentage unbound of (S)-warfarin (0.53%; 0.29%-0.82%) and (R)-warfarin (0.54%; 0.26%-0.96%). 4. The mean plasma clearances of warfarin enantiomers were 7.5 1 day-1 per 70 kg (2.5-22.1) for (S)-warfarin and 3.6 1 day-1 per 70 kg (1.6-8.8) for (R)-warfarin. There was a significant correlation between the estimated formation clearance of (S)-7-hydroxywarfarin and the clearance of (S)-warfarin, which accounted for much of the variability in the latter.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7917775      PMCID: PMC1364816          DOI: 10.1111/j.1365-2125.1994.tb04305.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Age as a determinant of sensitivity to warfarin.

Authors:  A M Shepherd; D S Hewick; T A Moreland; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

2.  Determinants of anticoagulant control in patients receiving warfarin.

Authors:  K O'Malley; I H Stevenson; C A Ward; A J Wood; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Stereospecific high-performance liquid chromatographic analysis of warfarin in plasma.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

4.  Volume shifts and protein binding estimates using equilibrium dialysis: application to prednisolone binding in humans.

Authors:  T N Tozer; J G Gambertoglio; D E Furst; D S Avery; N H Holford
Journal:  J Pharm Sci       Date:  1983-12       Impact factor: 3.534

Review 5.  The serum level approach to individualization of drug dosage.

Authors:  J Koch-Weser
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

6.  Pharmacokinetics and pharmacodynamics of warfarin at steady state.

Authors:  P A Routledge; P H Chapman; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

7.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

Authors:  C Banfield; R O'Reilly; E Chan; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  The warfarin-sulfinpyrazone interaction: stereochemical considerations.

Authors:  S Toon; L K Low; M Gibaldi; W F Trager; R A O'Reilly; C H Motley; D A Goulart
Journal:  Clin Pharmacol Ther       Date:  1986-01       Impact factor: 6.875

9.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

10.  Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

View more
  32 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

2.  Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.

Authors:  Drew R Jones; So-Young Kim; Michael Guderyon; Chul-Ho Yun; Jeffery H Moran; Grover P Miller
Journal:  Chem Res Toxicol       Date:  2010-05-17       Impact factor: 3.739

3.  A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.

Authors:  Qing Xi Ooi; Daniel F B Wright; R Campbell Tait; Geoffrey K Isbister; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

Review 4.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Lack of interaction between meloxicam and warfarin in healthy volunteers.

Authors:  D Türck; C A Su; G Heinzel; U Busch; E Bluhmki; J Hoffmann
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

6.  Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin.

Authors:  Berit Packert Jensen; Paul Ken Leong Chin; Rebecca Lee Roberts; Evan James Begg
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

7.  Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.

Authors:  Wenndy Hernandez; Keston Aquino-Michaels; Katarzyna Drozda; Shitalban Patel; Young Jeong; Harumi Takahashi; Larisa H Cavallari; Minoli A Perera
Journal:  Transl Res       Date:  2014-11-22       Impact factor: 7.012

8.  Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Xuemin Jiang; Kenneth M Williams; Winston S Liauw; Alaina J Ammit; Basil D Roufogalis; Colin C Duke; Richard O Day; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

9.  A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.

Authors:  Jamil A Haque; Matthew G McDonald; John D Kulman; Allan E Rettie
Journal:  Blood       Date:  2013-12-02       Impact factor: 22.113

Review 10.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.